Zynerba Pharmaceuticals Inc (ZYNE) stock is up nearly 21% this week and more than 69% over the last 30 days. ZYNE stock is down -5.60% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives ZYNE stock an overall score of 83 out of a possible 100.
That score is primarily influenced by a long-term technical score of 99. ZYNE’s score also includes a short-term technical score of 90. The fundamental score for ZYNE is 60. In addition to the average rating from Wall Street analysts, ZYNE stock has a mean target price of $16.30. This means analysts expect the stock to gain 66.67% over the next 12 months.
What’s Happening with ZYNE Stock Today
Zynerba Pharmaceuticals Inc (ZYNE) stock is higher by 2.93% while the S&P 500 is higher by 0.92% as of 12:26 PM on Tuesday, Apr 23. ZYNE is higher by $0.28 from the previous closing price of $9.50 on volume of 1,833,621 shares. Over the past year the S&P 500 is higher by 9.90% while ZYNE is down -5.60%. ZYNE lost -$2.61 per share in the over the last 12 months.